Predictive biomarkers candidates for patients with metastatic colorectal cancer treated with bevacizumab-containing regimen

Drug Metabolism and Personalized Therapy

Volumn 31, Issue 2, 2016, Pages 83-90

  González Vacarezza, Nicolás ^a   Alonso, Isabel ^b   Arroyo, Gustavo ^b,c   Martínez, Jorge ^b   De Andrés, Fernando ^a   Llerena, Adrián ^a   Estévez Carrizo, Francisco ^d  

^a UNIVERSITY OF EXTREMADURA   (Spain)

^b CASMU IAMPP   (Uruguay)

^c Facultad de Medicina Del CLAEH   (Uruguay)

^d UNIVERSIDAD DE MONTEVIDEO   (Uruguay)

Author keywords

bevacizumab; biomarker; cancer; colorectal

Indexed keywords

ANGIOPOIETIN 2; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR; LACTATE DEHYDROGENASE; MICRORNA 126; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; RGS PROTEIN; TUMOR MARKER; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; ANGIOGENESIS INHIBITOR;

ANGIOPOIETIN 2 GENE; BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; EPIDERMAL GROWTH FACTOR GENE; FMS-RELATED TYROSINE KINASE 1 GENE; GENE; GENETIC MARKER; HAPLOTYPE; HUMAN; HYPOXIA INDUCIBLE FACTOR 1ALPHA GENE; LACTATE DEHYDROGENASE BLOOD LEVEL; LACTATE DEHYDROGENASE GENE; METASTATIC COLORECTAL CANCER; MICRORNA 126 GENE; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR GENE; PROGRESSION FREE SURVIVAL; PROMIN 1 GENE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RGS5 GENE; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW; TREATMENT RESPONSE; VASCULAR ENDOTHELIAL GROWTH FACTOR A GENE; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1 GENE; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 GENE; COLORECTAL NEOPLASMS; DISEASE FREE SURVIVAL; METABOLISM; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; BEVACIZUMAB; BIOMARKERS; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; HUMANS; TREATMENT OUTCOME;

EID: 84974661147     PISSN: 23638907     EISSN: 23638915     Source Type: Journal    
DOI: 10.1515/dmpt-2015-0027     Document Type: Review

References (37)

1. International Agency for Research on Cancer. GLOBOCAN. Estimated Cancer Incidence Worldwide in 2012. Available at: http://globocan.iarc.fr/Pages/fact-sheets-cancer.aspx. Cited June 11, 2015.
2. Giantonio BJ, Levy DE, O'dwyer PJ, Meropol NJ, Catalano PJ, Benson AB 3rd, et al. A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200. Ann Oncol 2006;17:1399-403.
3. Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med (Berl) 1999;77:527-43.
4. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997;18:4-25.
5. Lee JC, Chow NH, Wang ST, Huang SM. Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur J Cancer 2000;36:748-53.
6. Tebbutt NC, Wilson K, Gebski VJ, Cummins MM, Zannino D, van Hazel GA, et al. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. J Clin Oncol 2010;28:3191-8.
7. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
8. Kabbinavar F, Irl C, Zurlo A, Hurwitz H. Bevacizumab improves the overall and progression-free survival of patients with metastatic colorectal cancer treated with 5-fluorouracil-based regimens irrespective of baseline risk. Oncology 2008;75:215-23.
9. Cunningham D, Lang I, Marcuello E, Lorusso V, Ocvirk J, Shin DB, et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol 2013;14:1077-85.
10. Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008;26:2013-9.
11. Cremolini C, Loupakis F, Masi G, Lonardi S, Zagonel V, Salvatore L, et al. FOLFOXIRI/bevacizumab versus FOLFIRI/ bevacizumab as first-line treatment in unresectable metastatic colorectal cancer: results of phase III TRIBE trial by GONO Group. Ann Oncol 2013;24(Suppl 4):iv21.
12. Van Cutsem E, Cervantes A, Nordlinger B, Arnold D, on behalf of the ESMO Guidelines. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014;25(Suppl 3):iii1-9.
13. National Comprehensive Cancer Network. Colon Cancer. Version 2.2015. Available at: www.nccn.org. Cited June 11, 2015.
14. European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP). European public assessment reports. Avastin: EPAR-Product Information. Available at: http://www. ema.europa.eu/docs/en-GB/document-library/EPAR-Product- Information/human/000582/WC500029271.pdf. Cited June 11, 2015.
15. U.S. Food and Drugs Administration. Avastin full prescribing information. Available at: http://www.accessdata.fda.gov/drugsatfda- docs/label/2015/125085s308lbl.pdf. Cited July 7, 2015.
16. Sibertin-Blanc C, Mancini J, Fabre A, Lagarde A, Del Grande J, Levy N, et al. Vascular endothelial growth factor A c.∗237C > T polymorphism is associated with bevacizumab efficacy and related hypertension in metastatic colorectal cancer. Dig Liver Dis 2015;47:331-7.
17. Hansen TF, Carlsen AL, Heegaard NH, Sørensen FB, Jakobsen A. Changes in circulating microRNA-126 during treatment with chemotherapy and bevacizumab predicts treatment response in patients with metastatic colorectal cancer. Br J Cancer 2015;112:624-9.
18. Jary M, Vernerey D, Lecomte T, Dobi E, Ghiringhelli F, Monnien F, et al. Prognostic value of angiopoietin-2 for death risk stratification in patients with metastatic colorectal carcinoma. Cancer Epidemiol Biomarkers Prev 2015;24:603-12.
19. Sohn BS, Park SJ, Kim JE, Kim KP, Hong YS, Suh C, et al. Singlenucleotide polymorphisms in the vascular endothelial growth factor pathway and outcomes of patients treated with firstline cytotoxic chemotherapy combined with bevacizumab for advanced colorectal cancer. Oncology 2014;87:280-92.
20. Volz NB, Stintzing S, Zhang W, Yang D, Ning Y, Wakatsuki T, et al. Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer. Pharmacogenomics J 2015;15:69-76.
21. Bécouarn Y, Cany L, Pulido M, Beyssac R, Texereau P, Le Morvan V, et al. FOLFIRI® and bevacizumab in first-line treatment for colorectal cancer patients: safety, efficacy and genetic polymorphisms. BMC Res Notes 2014;7:260.
22. Hansen TF, Christensen RD, Andersen RF, Sørensen FB, Johnsson A, Jakobsen A. MicroRNA-126 and epidermal growth factor-like domain 7-an angiogenic couple of importance in metastatic colorectal cancer. Results from the Nordic ACT trial. Br J Cancer 2013;109:1243-51.
23. Pohl A, El-Khoueiry A, Yang D, Zhang W, Lurje G, Ning Y, et al. Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumabbased chemotherapy. Pharmacogenomics J 2013;13:173-80.
24. Formica V, Palmirotta R, Del Monte G, Savonarola A, Ludovici G, De Marchis ML, et al. Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab. Int J Colorectal Dis 2011;26:143-51.
25. Loupakis F, Cremolini C, Yang D, Salvatore L, Zhang W, Wakatsuki T, et al. Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab. PLoS One 2013;8:e66774.
26. Gerger A, El-Khoueiry A, Zhang W, Yang D, Singh H, Bohanes P, et al. Pharmacogenetic angiogenesis profiling for first-line bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Clin Cancer Res 2011;17:5783-92.
27. Loupakis F, Ruzzo A, Salvatore L, Cremolini C, Masi G, Frumento P, et al. Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer. BMC Cancer 2011;11:247.
28. Kim JC, Ha YJ, Roh SA, Choi EY, Yoon YS, Kim KP, et al. Feasibility of proposed single-nucleotide polymorphisms as predictive markers for targeted regimens in metastatic colorectal cancer. Br J Cancer 2013;108:1862-9.
29. Loupakis F, Cremolini C, Fioravanti A, Orlandi P, Salvatore L, Masi G, et al. Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer. Br J Cancer 2011;104:1262-9.
30. Liu Y, Starr MD, Brady JC, Rushing C, Bulusu A, Pang H, et al. Biomarker signatures correlate with clinical outcome in refractory metastatic colorectal cancer patients receiving bevacizumab and everolimus. Mol Cancer Ther 2015;14:1048-56.
31. Zulato E, Bergamo F, De Paoli A, Griguolo G, Esposito G, De Salvo GL, et al. Prognostic significance of AMPK activation in advanced stage colorectal cancer treated with chemotherapy plus bevacizumab. Br J Cancer 2014;111:25-32.
32. Liu Y, Starr MD, Bulusu A, Pang H, Wong NS, Honeycutt W, et al. Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab. Cancer Med 2013;2:234-42.
33. Kara O, Duman BB, Kara B, Erdogan S, Parsak CK, Sakman G. Analysis of PTEN, VEGF, HER2 and P53 status in determining colorectal cancer benefit from bevacizumab therapy. Asian Pac J Cancer Prev 2012;13:6397-401.
34. Hansen TF, Christensen Rd, Andersen RF, Garm Spindler KL, Johnsson A, Jakobsen A. The predictive value of single nucleotide polymorphisms in the VEGF system to the efficacy of firstline treatment with bevacizumab plus chemotherapy in patients with metastatic colorectal cancer: results from the Nordic ACT trial. Int J Colorectal Dis 2012;27:715-20.
35. Bates DO, Catalano PJ, Symonds KE, Varey AH, Ramani P, O'Dwyer PJ, et al. Association between VEGF splice isoforms and progression-free survival in metastatic colorectal cancer patients treated with bevacizumab. Clin Cancer Res 2012;18:6384-91.
36. Otrock ZK, Hatoum HA, Musallam KM, Awada AH, Shamseddine AI. Is VEGF a predictive biomarker to anti-angiogenic therapy? Crit Rev Oncol Hematol 2011;79:103-11.
37. Weickhardt AJ, Williams D, Lee C, Simes J, Murone C, Wilson K, et al. Vascular endothelial growth factors (VEGF) and VEGF receptor expression as predictive biomarkers for benefit with bevacizumab in metastatic colorectal cancer (mCRC): Analysis of the phase III MAX study. J Clin Oncol 2011;29:Suppl: abstr3531.